636 related articles for article (PubMed ID: 14635078)
21. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
22. Tenascin-C in primary malignant melanoma of the skin.
Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S
Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480
[TBL] [Abstract][Full Text] [Related]
23. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
24. c -MYC amplification and expression in astrocytic tumors.
Faria MH; Khayat AS; Burbano RR; Rabenhorst SH
Acta Neuropathol; 2008 Jul; 116(1):87-95. PubMed ID: 18369647
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
[TBL] [Abstract][Full Text] [Related]
26. Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation.
Geffrotin C; Tricaud Y; Crechet F; Castelli M; Lefaix JL; Vaiman M
Radiat Res; 1998 May; 149(5):472-81. PubMed ID: 9588358
[TBL] [Abstract][Full Text] [Related]
27. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms.
Hauptmann S; Zardi L; Siri A; Carnemolla B; Borsi L; Castellucci M; Klosterhalfen B; Hartung P; Weis J; Stöcker G
Lab Invest; 1995 Aug; 73(2):172-82. PubMed ID: 7543628
[TBL] [Abstract][Full Text] [Related]
28. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
29. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
Erdamar S; Bagci P; Oz B; Dirican A
J BUON; 2006; 11(2):213-6. PubMed ID: 17318973
[TBL] [Abstract][Full Text] [Related]
30. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
31. Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis.
Jallo GI; Friedlander DR; Kelly PJ; Wisoff JH; Grumet M; Zagzag D
Neurosurgery; 1997 Nov; 41(5):1052-9. PubMed ID: 9361058
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of 5-lipoxygenase in high-grade astrocytomas.
Nathoo N; Prayson RA; Bondar J; Vargo L; Arrigain S; Mascha EJ; Suh JH; Barnett GH; Golubic M
Neurosurgery; 2006 Feb; 58(2):347-54; discussion 347-54. PubMed ID: 16462489
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 17 allelic loss in astrocytic tumors and its clinico-pathologic implications.
Muhammad AK; Yoshimine T; Maruno M; Tokiyoshi K; Takemoto O; Ninomiya H; Hayakawa T
Clin Neuropathol; 1997; 16(4):220-6. PubMed ID: 9266149
[TBL] [Abstract][Full Text] [Related]
35. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
[TBL] [Abstract][Full Text] [Related]
36. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.
Perry A; Aldape KD; George DH; Burger PC
Cancer; 2004 Nov; 101(10):2318-26. PubMed ID: 15470710
[TBL] [Abstract][Full Text] [Related]
37. The glucose transporter and blood-brain barrier of human brain tumors.
Guerin C; Laterra J; Hruban RH; Brem H; Drewes LR; Goldstein GW
Ann Neurol; 1990 Dec; 28(6):758-65. PubMed ID: 2178329
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of frizzled 9 in astrocytomas.
Zhang Z; Schittenhelm J; Guo K; Bühring HJ; Trautmann K; Meyermann R; Schluesener HJ
Neuropathol Appl Neurobiol; 2006 Dec; 32(6):615-24. PubMed ID: 17083476
[TBL] [Abstract][Full Text] [Related]
39. [Extracellular matrix of cerebral tumors with different invasiveness].
Klekner A; Varga I; Bognár L; Hutóczki G; Kenyeres A; Tóth J; Hanzély Z; Scholtz B
Ideggyogy Sz; 2010 Jan; 63(1-2):38-43. PubMed ID: 20420122
[TBL] [Abstract][Full Text] [Related]
40. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
